Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Infinity Regains Rights To Its Lead Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech pays nothing upfront to regain the Phase III HSP90 inhibitor, which is still on track in multiple clinical trials.
Advertisement

Related Content

Patient Deaths Stop Infinity Pharma’s Phase III HSP90 Trial In Cancer
Patient Deaths Stop Infinity Pharma's Phase III HSP90 Trial In Cancer
MedImmune Returns BiTE Compound To Micromet With An Option To Jump Back In
Atacicept R&D Cost Gone, ZymoGenetics Makes Plans
AstraZeneca/Infinity’s Hsp90 Inhibitor Advances In GIST
Change of Control: Why Getting it Right Matters Even More
Reviewing Five Years of Big Pharma's Biotech Acquisitions
Astra Wins MedImmune Auction; $15.6 Billion Price Tag Raises Eyebrows
The $100 Million IND
MedImmune Bolsters Oncology Pipeline Under Agreement With Infinity

Topics

Advertisement
UsernamePublicRestriction

Register

PS067114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel